ulinastatin

AssetAlso called AER-002, BIKUNIN, MIRACLID, ESTOTIN

Inhibits serine proteases, including trypsin and neutrophil elastase, limiting inflammation and tissue injury.

Stage
Phase 1
Modality
Protein or enzyme
Target
Not known
1
Indication
1
Trial
1
Developer

Trial NCT07923578 is still running. Trial NCT07923578 updated in its registry on Nov 6, 2026. clinicaltrials.gov

Indications

1

In the full profile

  • Owner and partners1
  • Trials1
  • Evidence for its targets1
  • Signals4

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets